Intensity Therapeutics (INTS) & Its Rivals Head to Head Contrast

Intensity Therapeutics (NASDAQ:INTS) is one of 610 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its rivals? We will compare Intensity Therapeutics to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Volatility & Risk

Intensity Therapeutics has a beta of 2.94, meaning that its stock price is 194% more volatile than the S&P 500. Comparatively, Intensity Therapeutics’ rivals have a beta of 0.98, meaning that their average stock price is 2% less volatile than the S&P 500.

Valuation & Earnings

This table compares Intensity Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Intensity Therapeutics	N/A	-$11.61 million	-0.82
Intensity Therapeutics Competitors	$887.60 million	$64.70 million	-29.32

Intensity Therapeutics’ rivals have higher revenue and earnings than Intensity Therapeutics. Intensity Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Intensity Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
Intensity Therapeutics Competitors	-811.78%	-695.88%	-28.42%

Analyst Ratings

This is a summary of recent ratings and price targets for Intensity Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1	0	2	1	2.75
Intensity Therapeutics Competitors	8498	13209	40361	1394	2.55

Intensity Therapeutics currently has a consensus target price of $37.50, indicating a potential upside of 696.18%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 70.22%. Given Intensity Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Intensity Therapeutics is more favorable than its rivals.

Institutional & Insider Ownership

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 51.3% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 7.1% of Intensity Therapeutics shares are held by insiders. Comparatively, 12.5% of shares of all “MED – BIOMED/GENE” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Intensity Therapeutics beats its rivals on 7 of the 13 factors compared.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.